Xu, Qixia
Fu, Qiang
Li, Zi
Liu, Hanxin
Wang, Ying http://orcid.org/0000-0002-2571-9367
Lin, Xu
He, Ruikun
Zhang, Xuguang
Ju, Zhenyu
Campisi, Judith
Kirkland, James L. http://orcid.org/0000-0003-1676-4905
Funding for this research was provided by:
National Natural Science Foundation of China (81472709, 31671425, 31871380, 82130045)
Article History
Received: 14 April 2021
Accepted: 13 October 2021
First Online: 6 December 2021
Competing interests
: By-Health funds research on senolytics in Y.S.’s laboratory. Y.S., Q.X., R.H. and X.Z. are named inventors on a technical patent related to senolytic screening and pharmacological evaluation (202011428651.2). Q.F. is the founder and CEO of Shandong Cellogene Pharmaceutics, for which Y.S. serves as a scientific advisor. J.C. is a scientific founder of Unity Biotechnology, which develops senolytic therapies, and holds patents related to the induction and detection of senolysis. J.L.K. has financial interest related to this research, with patents on senolytic drugs held by the Mayo Clinic. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic Conflict of Interest policies. The remaining authors declare no competing interests.